Novo Nordisk A/S - Reduction of the share capital


Bagsværd, Denmark, 23 April 2014 - At Novo Nordisk's Annual General Meeting on 20 March 2014, it was decided to reduce the company's B share capital from DKK 442,512,800 to DKK 422,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 100,000,000 B shares of DKK 0.20 each.

Further information

Media:
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Frank Daniel Mersebach +45 3079 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Jannick Lindegaard (US) +1 609 235 8567 jlis@novonordisk.com

Company announcement No 25 / 2014


Attachments

Reduction of the share capital